Navigation Links
New cell type offers immunology hope
Date:6/14/2011

A team of Australian scientists has discovered a new type of cell in the immune system.

The new cell type, a kind of white blood cell, belongs to a family of T-cells that play a critical role in protection against infectious disease.

Their findings could ultimately lead to the development of novel drugs that strengthen the immune response against particular types of infectious organisms.

It is also potentially significant for many other important diseases including allergies, cancer and coronary artery disease.

The research team includes Dr Adam Uldrich and Professor Dale Godfrey from the University of Melbourne, Dr Onisha Patel and Professor Jamie Rossjohn from Monash University and Professor Mark Smyth from the Peter MacCallum Cancer Institute.

The discovery, published in the international journal Nature Immunology, is a fundamental advance in understanding the different components of the immune system and how this system casts a net wide enough to catch all kinds of different infectious organisms.

Typically, when the body is threatened with bacterial or viral infection, molecules called T-cell receptors interact with protein fragments (called peptides) from the bacterium or virus, triggering the immune response. This process has been widely studied and leads to the killing of microbes and protection against severe infection.

While the immune system is known to focus on proteins from viruses and bacteria, some T-cells in the immune system (known as NKT cells) can recognise lipid-based, or fatty, molecules. As such, there is great enthusiasm for the potential of these lipid-sensing T-cells in the development of novel vaccines. This team have identified a new type of NKT cell that can specifically target lipids found in the cell walls of bacteria, including Mycobacteria.

Professor Dale Godfrey from the University of Melbourne said the discovery is significant and opens the door
'/>"/>

Contact: Rebecca Scott
rebeccas@unimelb.edu.au
61-383-440-181
University of Melbourne
Source:Eurekalert

Page: 1 2

Related biology news :

1. Worm genome offers clues to evolution of parasitism
2. Advance offers revolution in food safety testing
3. Light pollution offers new global measure of coral reef health
4. Rong Li Lab offers insight into adaptive ability of cells
5. International public-private partnership offers new paradigm for medicinal chemistry
6. UC Davis discovery offers hope for treating kidney cancer
7. New paper offers key insights into how new species emerge
8. Study offers clues to beating hearing loss
9. Fighting global warming offers growth and development opportunities
10. Brown-led team offers first look at how bats land
11. Star Trek-like technology offers noninvasive monitor for patients and athletes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... and tuberculosis live side-by-side. Worldwide there are approximately ... nearly all of them occurring where tuberculosis is ... or BCG, provides only partial protection against both ... is needed to combat both diseases. UCLA-led research ... diseases., In a study published in the September ...
(Date:8/19/2014)... Scientists at the Houston Methodist Research Institute have figured ... using a pipette -- a common laboratory tool that,s ... preliminary test results in a recent issue of the ... "Studying single cells and their unique functions has become ... faculty member Lidong Qin, Ph.D., the project,s principal investigator. ...
(Date:8/19/2014)... awarded a nearly $40,000 grant from the National Center ... the National Park Service (NPS) and U.S. Department of ... of the energy efficiency and cost effectiveness of radiant ... , Radiant barriers are reflective thermal insulations commonly fitted ... reducing the amount of heat emitted in the direction ...
Breaking Biology News(10 mins):New vaccine shows promise as stronger weapon against both tuberculosis and leprosy 2Moving single cells around -- accurately and cheaply 2UTSA researcher awarded $38K+ to evaluate energy efficiency options for historic homes 2UTSA researcher awarded $38K+ to evaluate energy efficiency options for historic homes 3
... the release of GeneLinker(TM) Gold and Platinum ... and Proteomics Analysis,Software products.,"The new releases are ... data, a high priority for many of ... Protein Biomarker Package into the,latest versions of ...
... will be brought to the marketplace, giving laboratories ... Technology Transfer GmbH (EMBLEM), the commercial entity of ... that it has signed a licensing deal with ... technology called SPIM (Selective Plane Illumination Microscopy). , ...
... There's a,paradigm in life science and drug development : ... occasions I've,seen very promising drugs candidates or related research ... it, even if millions would have,been saved worldwide. The ... drug candidate that affect a "profitable" disease in addition ...
Cached Biology News:Improved Outcomes Releases GeneLinker(TM) Gold and Platinum Version 4.6 2Improved Outcomes Releases GeneLinker(TM) Gold and Platinum Version 4.6 3The transparent organism: EMBLEM and Carl Zeiss give labs a unique look at life 2Finding Cures For Tropical Diseases: Is Open Source An Answer? 2
(Date:8/19/2014)... In November 2012, the European Union (EU) mandated use ... a new PSUR – responding to the increasing need to ... drug. Adopted in many regions, the main objectives of the ... and critical analysis of new or emerging information on the ... evidence of the potential benefits of a drug; and , ...
(Date:8/18/2014)... 2014) -- A new therapy developed by researchers ... College of Medicine and Columbia University Medical Center ... interventional cardiovascular disease treatment. , The researchers ... molecular therapy could selectively inhibit blood vessel re-narrowing ... procedure using a balloon catheter to open narrowed ...
(Date:8/18/2014)... Global HIV Infection Drug Market and Pipeline Insight ... of HIV infection and the number of deaths due to ... rate across the globe. It has been estimated that the ... in 2013, with the rates for children being even much ... infection rates has been the improved access to antiretroviral drugs ...
(Date:8/18/2014)... Toronto, Canada (PRWEB) August 18, 2014 ... land of opportunity for the clinical research industry. ... clinical trials due to its aging population; a ... in chronic diseases; a densely populated pool of ... enrolment. , Notwithstanding these positive points, China also ...
Breaking Biology Technology:Top Five Best Practices for Developing Your Periodic Benefit Risk Evaluation Report (PBRER), New Webinar Hosted by Xtalks 2Selective therapy may improve artery repair after interventional cardiovascular procedures 2Selective therapy may improve artery repair after interventional cardiovascular procedures 3Global HIV Infection Drug Market Overview 2Global HIV Infection Drug Market Overview 3Global HIV Infection Drug Market Overview 4China – Land of Opportunities & Challenges for the Clinical Research Industry, New Webinar Hosted by Xtalks 2
... 16 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: ... company focused on endocrine therapy and oncology, today announced ... its partner and licensee for perifosine in the North ... from the U.S. Food and Drug Administration (FDA) for ...
... , , The ... , , WASHINGTON, Sept. 16 The Foundation ... national animal research education campaign. Since 2004, public support for humane ... points. The ResearchSaves campaign is designed to counter this drop in ...
... , NEW HAVEN, Conn., Sept. 16 Rib-X ... commercialization of novel drugs for the treatment of multi-antibiotic resistant ... the Company,s Board of Directors, succeeding Joseph Amprey, MD, Ph.D. ... of MedImmune, Chief Executive Officer of AstraZeneca North America, and ...
Cached Biology Technology:AEterna Zentaris Partner, Keryx Biopharmaceuticals, Receives Orphan-Drug Designation for Perifosine (KRX-0401) for the Treatment of Multiple Myeloma 2AEterna Zentaris Partner, Keryx Biopharmaceuticals, Receives Orphan-Drug Designation for Perifosine (KRX-0401) for the Treatment of Multiple Myeloma 3Biomedical Research Organization Launches Groundbreaking National TV Campaign 2Rib-X Pharmaceuticals, Inc. Appoints Tony Zook of MedImmune to Board of Directors 2Rib-X Pharmaceuticals, Inc. Appoints Tony Zook of MedImmune to Board of Directors 3
The PDS-1000 He Hepta system includes the PDS-1000 He biolistic system and the Hepta adaptor....
... system, 220-240 V, is used for ... The system includes the BioLogic LP ... MV-6 injection valve, proportioning valve or ... and fittings kit, column and conductivity ...
... have been developed for affinity capture ... variety of ProteinChip chemical surfaces allow ... their unique biochemical properties. Each chip ... sample comparison, and the chips are ...
... been developed for affinity capture of ... of ProteinChip chemical surfaces allow differential ... unique biochemical properties. Each chip has ... comparison, and the chips are color-coded ...
Biology Products: